Madrigal Pharmaceuticals ...
(MDGL)
undefined
undefined%
At close: undefined
304.50
0.67%
After-hours Dec 13, 2024, 04:00 PM EST
Madrigal Pharmaceuticals Inc. Analyst Ratings
Total Analysts
13
Consensus Rating
Buy
Price Target
377
Upside
24.64
Ratings History
Analyst | Firm | Rating | Action | Price Target | Date |
Prakhar Agrawal (0)
| Cantor Fitzgerald | Hold | Reiterates | n/a | Nov 20, 2024 |
Mayank Mamtani (1.48)
| B. Riley Securities | Hold | Maintains | 194 236 | Nov 5, 2024 |
Eliana Merle (0)
| UBS | Strong Buy | Maintains | 411 441 | Nov 1, 2024 |
Trade Smarter, Not Harder
Cut through market noise with actionable insights that actually help you make confident investment decisions. No more endless research or gut-based guessing.
- Unlimited access to all data and tools
- Unlimited access to all data and tools, giving you the edge over everyone else in the market.
- Realtime Options Data
- Instant access to live options data to spot opportunities and trade with precision before the market moves.
- Top Wallstreet Analyst Ratings
- Follow ratings from the best analysts on Wall Street to stay ahead.
- Up to 30 years financial history
- We deliver premium Wall Street data with top-tier accuracy and up to 30 years of history.
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.